UFP Technologies Inc.

UFPT

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0000914156

A/B

on the A/B boundary of 370 graded peers in healthcare

rank 67 of 370; percentile 17.9; sampling error 2.5 points; lower is stronger

A B C D E

A/B, the bull




Scoreboard	
Profitability	C percentile 46.0
Solvency	B/C percentile 39.4
Growth and financing	B percentile 23.8
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $655.1M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress
Inputs computable	10 of 14
Graded from	filings received through Feb 27, 2026 240 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026
Last close	$296.08 2026-10-23; market equity $2.3B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 27, 2026

The Company is a contract development and manufacturing organization that specializes in single-use and single-patient medical devices. The Company is a vital link in the medical device supply chain and a valued outsourcing partner to many of the world's top medical device manufacturers. Our single-use and single-patient devices and components are used in a wide range of medical devices and packaging for minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants. The Company was incorporated in the State of Delaware in 1993.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight


Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 46.0						
Gross profitability	26.0%	32.3%		55.3	368	2025-12-31
Return on invested capital	14.5%	9.3%		32.9	74	2025-12-31
Accruals ratio	(3.7%)	(6.6%)		67.6	807	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	1.7 pts	2.8 pts	28.2	242	2025-12-31
Solvency, sleeve percentile 39.4					
Twelve-month failure probability	not computable	0.07%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	6.00	(0.33)	16.0	752	2025-12-31
Net debt to EBITDA	1.03x	1.82x	41.9	75	2025-12-31
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31					
Current ratio	2.68x	2.94x	60.3	834	2025-12-31
Growth and financing, sleeve percentile 23.8					
Revenue growth, three-year compound	19.4%	10.1%	32.0	413	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31					
Reinvestment rate	not computable	37.1%			
latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31					
Asset growth, three years	20.1%	2.1%	21.2	700	2025-12-31
Net share issuance, one year	0.4%	2.5%	18.1	636	2026-02-19

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
62	Definium Therapeutics, Inc. (DFTX)	16.5	A	dilution
63	Natures Sunshine Products Inc. (NATR)	16.8	A	fortress balance sheet
64	Alnylam Pharmaceuticals, Inc. (ALNY)	17.1	A	
65	Acadia Pharmaceuticals Inc. (ACAD)	17.3	A	
66	Aurinia Pharmaceuticals Inc. (AUPH)	17.6	A/B	
67	UFP Technologies Inc. (UFPT)	17.9	A/B	
68	Conmed Corp. (CNMD)	18.2	A/B	
69	Dexcom Inc. (DXCM)	18.4	A/B	fortress balance sheet
70	Orthofix Medical Inc. (OFIX)	18.7	A/B	
71	InnovAge Holding Corp. (INNV)	19.0	A/B	fortress balance sheet
72	Adma Biologics, Inc. (ADMA)	19.2	A/B	late filer, fortress balance sheet

What the price implies

at the 2026-10-23 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	49.3%	7.7%	76
Distance from 52-week high	(11.7%)	(31.4%)	75
EBIT to enterprise value	3.8%	(1.5%)	71
Free cash flow yield	2.5%	(1.0%)	68
Book value to price	0.20	0.28	41
Sales to price	0.26	0.30	45

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Composite equity issuance, five years	3.0%	20.5%	30
Relative strength against the sector, log excess return	0.19	(0.14)	76

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 5 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$9.0M
Operating cash flow, four quarters	$71.6M
Months of runway	not finite
Days since last periodic filing	80 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	$33.2M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$170.4M	2025-12-31	2026-02-27	10-K	26-012816
2	assets	us-gaap:Assets	$655.1M	2025-12-31	2026-02-27	10-K	26-012816
3	operating income	us-gaap:OperatingIncomeLoss	$92.3M	2025-12-31	2026-02-27	10-K	26-012816
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$82.5M	2025-12-31	2026-02-27	10-K	26-012816
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$14.2M	2025-12-31	2026-02-27	10-K	26-012816
6	total debt	us-gaap:LongTermDebt	$135.5M	2025-12-31	2026-02-27	10-K	26-012816
7	book equity	us-gaap:StockholdersEquity	$423.9M	2025-12-31	2026-02-27	10-K	26-012816
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$20.3M	2025-12-31	2026-02-27	10-K	26-012816
9	total debt	us-gaap:LongTermDebt	$189.4M	2024-12-31	2026-02-27	10-K	26-012816
10	book equity	us-gaap:StockholdersEquity	$342.8M	2024-12-31	2026-02-27	10-K	26-012816
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$13.4M	2024-12-31	2026-02-27	10-K	26-012816
12	net income	us-gaap:NetIncomeLoss	$68.3M	2025-12-31	2026-02-27	10-K	26-012816
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$91.9M	2025-12-31	2026-02-27	10-K	26-012816
14	assets	us-gaap:Assets	$629.0M	2024-12-31	2026-02-27	10-K	26-012816
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$602.8M	2025-12-31	2026-02-27	10-K	26-012816
16	gross profit	us-gaap:GrossProfit	$146.7M	2024-12-31	2026-02-27	10-K	26-012816
17	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$504.4M	2024-12-31	2025-03-03	10-K	25-001192
18	gross profit	us-gaap:GrossProfit	$112.2M	2023-12-31	2026-02-27	10-K	26-012816
19	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$400.1M	2023-12-31	2025-03-03	10-K	25-001192
20	gross profit	us-gaap:GrossProfit	$90.3M	2022-12-31	2025-03-03	10-K	25-001192
21	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$353.8M	2022-12-31	2025-03-03	10-K	25-001192
22	gross profit	us-gaap:GrossProfit	$51.1M	2021-12-31	2024-02-29	10-K	24-001078
23	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$206.3M	2021-12-31	2024-02-29	10-K	24-001078
24	current assets	us-gaap:AssetsCurrent	$201.0M	2025-12-31	2026-02-27	10-K	26-012816
25	current liabilities	us-gaap:LiabilitiesCurrent	$74.9M	2025-12-31	2026-02-27	10-K	26-012816
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$374.8M	2025-12-31	2026-02-27	10-K	26-012816
27	liabilities	us-gaap:Liabilities	$231.2M	2025-12-31	2026-02-27	10-K	26-012816
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$19.1M	2025-12-31	2026-02-27	10-K	26-012816
29	operating income	us-gaap:OperatingIncomeLoss	$80.9M	2024-12-31	2026-02-27	10-K	26-012816

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

30	interest expense	us-gaap:InterestExpense	$8.1M	2024-12-31	2025-03-03	10-K	25-001192
31	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$66.6M	2024-12-31	2026-02-27	10-K	26-012816
32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$9.7M	2024-12-31	2025-03-03	10-K	25-001192
33	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$41.3M	2023-12-31	2026-02-27	10-K	26-012816
34	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$10.5M	2023-12-31	2025-03-03	10-K	25-001192
35	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$17.7M	2022-12-31	2025-03-03	10-K	25-001192
36	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$13.8M	2022-12-31	2025-03-03	10-K	25-001192
37	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$14.3M	2021-12-31	2024-02-29	10-K	24-001078
38	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$5.4M	2021-12-31	2024-02-29	10-K	24-001078
39	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$14.7M	2024-12-31	2026-02-27	10-K	26-012816
40	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$73.0M	2024-12-31	2026-02-27	10-K	26-012816
41	income tax	us-gaap:IncomeTaxExpenseBenefit	$14.0M	2024-12-31	2026-02-27	10-K	26-012816
42	current assets	us-gaap:AssetsCurrent	$194.9M	2024-12-31	2026-02-27	10-K	26-012816
43	current liabilities	us-gaap:LiabilitiesCurrent	$76.3M	2024-12-31	2026-02-27	10-K	26-012816
44	current assets	us-gaap:AssetsCurrent	$144.6M	2023-12-31	2025-03-03	10-K	25-001192
45	current liabilities	us-gaap:LiabilitiesCurrent	$58.2M	2023-12-31	2025-03-03	10-K	25-001192
46	assets	us-gaap:Assets	$404.1M	2023-12-31	2025-03-03	10-K	25-001192
47	assets	us-gaap:Assets	$378.2M	2022-12-31	2024-02-29	10-K	24-001078
48	shares outstanding	dei:EntityCommonStockSharesOutstanding	7,713,300	2026-02-19	2026-02-27	10-K	26-012816
49	shares outstanding	dei:EntityCommonStockSharesOutstanding	7,680,305	2025-02-25	2025-03-03	10-K	25-001192

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.